Twitter Beğeni Hilesi

My Top 10 Gastrointestinal Cancer Abstracts #ESMO24 ESMO - Eur. Oncology

Practice needs often surpass clinical trials- saw in clinic today: ☑️ Female, 67y, 30 packet years, PS=1 ☑️Adeno st4, (+) effusion, bone Mets ☑️ Compound EGFR mutations: Exon20 (p.S768I) plus Exon21 ( p.L861Q) ☑️PDL1=30% What would be your 1st line treatment? #LCSM #some

Brilliant algorithm on how to approach thrombocytosis Source: Matthew Ho

Thank you all for your great feedback, happy to have triggered brainstorming !! Some comments to facilitate discussion: 1. Surprised that most popular choice thus far is chemo + ami, actually this is a point mutation of Exon 20 and not an insertion, so this patient is not a

Check out all the great pre-conference workshops at #WCLC24 - key aspects 🙌 Many are hands on experiences 🌎 Global Faculty 🤼 Practical and effective tips 🤝 Great place to start collaborations OncoAlert OncoDaily Oncology Brothers

SignifyMD & Oncology News Central proudly present an exciting event at the #WCLC2024, featuring admired oncologists Dr. Rahul & Dr. Rohit Gosain Oncology Brothers​ Join us! bit.ly/RegisterHere_A… IASLC Dr. Estela Rodriguez Eric K. Singhi, MD Charu Aggarwal, MD, MPH, FASCO Narjust Florez, MD, FASCO Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation

📣Excited to join the Oncology Brothers, great colleagues & experts, Charu Aggarwal, MD, MPH, FASCO Narjust Florez, MD, FASCO Jarushka Naidoo Dr. Estela Rodriguez Eric K. Singhi, MD on this EDUCATIONAL event during #WCLC24 on latest #Advancements in #LungCancer Tx. 📆 Sun 9/8/24 at 6 PM Join & Register👉 bit.ly/AIOWCLC24

🤩Excited to join Oncology Brothers & thoracic oncology colleagues Charu Aggarwal, MD, MPH, FASCO Narjust Florez, MD, FASCO Jarushka Naidoo Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation Eric K. Singhi, MD on this EDUCATIONAL event translating the science for today’s clinical practice during #WCLC24 IASLC on latest #Advancements in #LungCancer

I am registered and looking forward to this all-star lineup! Oncology Brothers Charu Aggarwal, MD, MPH, FASCO Eric K. Singhi, MD Narjust Florez, MD, FASCO Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation Jarushka Naidoo Dr. Estela Rodriguez #WCLC24 #LCSM

Two weeks to #ESMO24. Multiple important breast onc trials readouts across disease subtypes, including OS from KN522, DB12, 4y of NATALEE, CAPItello290, phase 1 studies of novel ADCs, IO, targeted drugs, and so much more. The countdown is on. See you soon in Barcelona! 🇪🇸 #bcsm

Intracranial activity of Tarlatamab in 2L SCLC in Ph I DeLLphi-300 Trial Journal of Clinical Oncology: - 152pts, mfollow-up 12.1m - intracranial ORR 62.5% (all prior RT) - mOS 17.5m, ORR 25% Important data, now to make this easier to give to patients OncoAlert #LCSM ascopubs.org/doi/10.1200/JC…

Just in Annals of Oncology 👉on the heels of the recent approval of belzutifan in mRCC #kidneycancer , herein we show in a ph2 randomized trial👉more belzutifan (200 mg vs 120 mg QD) was not better👇Link: tinyurl.com/nrsxp8s4 UroToday.com OncoAlert KidneyCAN Huntsman Cancer Institute

Real world data from Italy on #MET exon 14 mutations in NSCLC ESMO Open. In 146 pts with #METex14 NSCLC, 38% given capmatinib and 23% tepotinib. RR to MET inhibitors was 46% as 1L therapy, 33% in later lines. mPFS 6.6m, mOS 10.7m, intracranial RR 41%. esmoopen.com/article/S2059-…

Dear Colleagues, The OncoAlert 🚨Network Presents OUR Picks of TOP 🔟Abstracts to be Presented at #ESMO24 This List Curated by: #OncoAlertAF Leads Elisa Agostinetto 🇮🇹 Elisabetta Bonzano MD, PhD 🇮🇹 Luca Arecco, MD 🇮🇹 Gil Morgan, MD 🇺🇸 With our distinguished OncoAlert Faculty: Sara Tolaney

SignifyMD & Oncology News Central proudly present an exciting event at the #WCLC2024, featuring esteemed oncologists Dr. Rahul & Dr. Rohit Gosain Oncology Brothers​ Join us! bit.ly/RegisterHere_A… IASLC Dr. Estela Rodriguez Eric K. Singhi, MD Charu Aggarwal, MD, MPH, FASCO Narjust Florez, MD, FASCO Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation

Adj abemaciclib preferred for high-risk HR+ EBC due to longer follow-up, deeper benefits, & shorter ⏰ of Rx. For patients intolerant to abema, ribociclib could be an option, especially for those outside monarchE with high-risk features. #OncTwitter OncoAlert #bcsm Sara Tolaney

Our Dear friends the Oncology Brothers with🔟anticipated Practice changing Abstracts to be Presented at #ESMO24 !!

Join us on Friday, Sept 13 12-1p EST for the beginning of our SmallCellSMASHERS Fireside Chat Speaker Series FB Live, featuring a conversation with Anne Chiang in partnership w/ LUNGevity Foundation We will discuss breakthroughs for limited- & extensive-stage, exciting trials, & Q&A #LCSM

Omission of 5-FU Bolus From Multidrug Regimens 🔍Retrospective study with ~12,000 pts in GI cancer 💥Omitting 5-FU bolus had no negative impact on survival (FOLFOX, FOLFIRI, FOLFIRINOX) 💥Associated with a significant reduction in toxicity jnccn.org/view/journals/…